GuideMe Books: A New Concept in Publishing

Prevent Blindness, the nation’s oldest volunteer eye health and safety organization, has launched a unique new resource, “GuideMe”, designed for those who have been diagnosed with Age-related Macular Degeneration (AMD) or Diabetic Macular Edema (DME). The intent of the GuideMe books is to simulate as accurately as possible a post-diagnosis consultation with a doctor or therapist. They [Read More]

Ocata's Stem Cell Trials Entering Phase 2

Results from First Cohort Expected in the Second Quarter of 2016 Acucela (formerly Ocata) has announced that the first patient has been enrolled in the company’s Phase 2 clinical trial using Ocata’s proprietary RPE cells in patients with atrophic (dry) age-related macular degeneration (AMD). The purpose of the trial is to evaluate safety and explore efficacy as compared [Read More]

Long-term Treatment for Wet AMD Enters Phase 2 Trials

Neurotech Pharmaceuticals, Inc. has announced that they have enrolled the first patient in their multicenter Phase 2 clinical trial of NT-503 Encapsulated Cell Therapy (ECT) for the long-term treatment of wet macular degeneration (AMD). NT-503 is a unique vascular endothelial growth factor (VEGF) receptor protein continuously produced by Neurotech’s versatile ECT implant. “This landmark proof-of-concept [Read More]

New Book On Eye Nutrition Answers Common Questions

Leading nutrition expert Jeffrey Anshel, OD, FAAO, has just published a new book titled “What You Must Know about Food and Supplements for Optimal Vision Care.” It is a practical guide to diets, supplements and lifestyles for peak ocular health, with excellent information about how to integrate supplements with mainstream medical treatments whenever appropriate. Dr. [Read More]